Your search for dabigatran returned 14 results

Despite trend toward lower stroke risk with high dose

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding

Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.

For patients taking dabigatran, the risk of gastrointestinal bleeding (GIB) is reduced with use of gastroprotective agents.

Non-vitamin K oral anticoagulants exhibit variable effects on coagulation assays, according to a new study.

For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.

New recommendations have been developed for the optimum management of atrial fibrillation.

Most people with nonvalvular atrial fibrillation (NVAF) should be taking oral anticoagulants to prevent stroke.

For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.